Biologics is expected to remain the largest segment in the global biopharmaceutical CMO & CRO market

DALLAS, TX / October 13, 2021 /An exciting new study from the team of Lucintel found that biopharmaceutical CMO & CRO market is expected to grow at a CAGR of 7%-9%. There are significant money making opportunities available in this market and companies planning to enter this market need to differentiate in order to maximize their return on investment.

Download Brochure of this report by clicking on

The biopharmaceutical CMO & CRO market is segmented based on product, service, source, and region. In this market, biologics are the largest segment by product, whereas mammalian are largest by source. Players can benefit from the available opportunities like presence of a large number of small and mid-size biopharmaceutical entities (SMEs) that are lacking the resources and budget to establish facilities with well-equipped resources.

Lonza, Rentschler Biotechnologie, Boehringer Ingelheim, JRS Pharma, Inno Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies, Samsung BioLogics, and Toyobo are some of the major players profiled in this 150 page report.

Some of the Key Questions answered in this exclusive report are:

Q.1 What are some of the most promising, high-growth opportunities for the biopharmaceutical CMO & CRO market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, vaccines, antisense, RNAi, & molecular therapy, and others) and biosimilars), service (contract manufacturing (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging) and contract research (oncology, inflammation & immunology, cardiology, neuroscience, and others)), source (mammalian and non-mammalian), and region (North America, Europe, Asia Pacific, and Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 What are the business risks and threats to the biopharmaceutical CMO & CRO market?

Q.4 What are some changing demands of customers in the biopharmaceutical CMO & CRO market?

Q.5 What are the new developments in the biopharmaceutical CMO & CRO market? Which companies are leading these developments?

Q.6 What strategic initiatives are being implemented by key players for business growth?

Q.7 What are some of the competitive products and processes in this biopharmaceutical CMO & CRO area and how big of a threat do they pose for loss of market share via product substitution?

Q.8 What M&A activity has occurred in the last 5 years in this biopharmaceutical CMO & CRO market?

This unique report from Lucintel will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit

Brandon Fitzgerald
Dallas, Texas, USA
Tel. 972.636.5056
Cell: 303.775.0751

Leave a comment

Your email address will not be published. Required fields are marked *